Graphic image of a red thumbs down against a blue background
Biotech

FDA advisers resoundingly reject BrainStorm's ALS drug

FDA advisers agreed with staffers' concerns about BrainStorm's cell therapy for ALS, voting resoundingly against the treatment's potential efficacy.
Max Bayer Sep 27, 2023 6:04pm
Alzheimers brain

Roche pays Ionis $60M to license Alzheimer's, Huntington's drugs

Sep 27, 2023 8:56am
Emulate

Improving the Drug Development Process with Organ-Chips

Sep 25, 2023 8:00am
Gilead

Gilead ends phase 3 leukemia trial early after data disappoint

Sep 27, 2023 7:48am
IPMai

Uncover the Rare Disease Patient Journey

Sep 25, 2023 8:00am
Photo of 100 bills overlapping each other in the frame

Pfizer signs $331M deal with Ginkgo for unspecified targets

Sep 27, 2023 9:50am
Medtech News

Philips suppressed concerns years before CPAP recall: ProPublica

Sep 27, 2023 1:58pm

Deep Genomics puts forward AI model for generating RNA therapies

Sep 27, 2023 11:16am

First patient implanted with Onward BCI to restore arm function

Sep 27, 2023 10:57am

Rockley plows ahead in developing noninvasive glucose sensor

Sep 26, 2023 1:11pm